Cilazapril

Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113) . Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure[1][2][3][4][5].

Product Specifications

CAS Number

[88768-40-5]

Product Name Alternative

Ro 31-2848

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Angiotensin-converting Enzyme (ACE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cilazapril.html

Solubility

10 mM in DMSO

Smiles

O=C([C@@H]1CCCN2N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)CCC2)=O)O

Molecular Formula

C22H31N3O5

Molecular Weight

417.50

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24.|[2]Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9 (1) : p. 39-44.|[3]Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27 Suppl 2 (Suppl 2) :139S-150S.|[4]Bhutto IA, et al. Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Life Sci. 1999;64 (3) :PL27-39.|[5]Asahi T, et al. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid. 2001 Nov;11 (11) :1009-15.